GALT insider trading
NasdaqCM HealthcareGALECTIN THERAPEUTICS INC: insider trade history from SEC Form 4 filings.
About GALECTIN THERAPEUTICS INC
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Company website: galectintherapeutics.com
GALT insider activity at a glance
FilingIQ tracks 538 insider transactions for GALT in filings since Feb 3, 2015. The most recent transaction is dated Jul 31, 2026.
Across the full history, 87 open-market purchases
and 174 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on GALT insider trades is 53.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest GALT Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for GALT?
- FilingIQ tracks 538 Form 4 insider transactions for GALT (GALECTIN THERAPEUTICS INC), covering filings from Feb 3, 2015 onwards. 4 of those are dated within the last 90 days.
- Are GALT insiders net buyers or net sellers?
- Across the full Form 4 history for GALT, 87 transactions (16%) were open-market purchases and 174 (32%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does GALT insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is GALT in?
- GALECTIN THERAPEUTICS INC (GALT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $188.28M.
Methodology & sources
Every GALT insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.